Literature DB >> 3142256

The immunohistology of IgA nephropathy.

J C Jennette1.   

Abstract

The glomerular immunohistologic characteristics of 180 patients with IgA nephropathy (IgAN), defined by 2+ or greater (out of 0 to 4+) mesangial IgA-dominant or codominant immunostaining and no evidence for systemic lupus erythematosus, were compared with those of 84 patients with proliferative lupus glomerulonephritis and 254 patients with other forms of proliferative glomerulonephritis. The IgAN population increased in number by only 5% if the IgA immunostaining criterion was lowered to 1+, and it decreased by only 2% if IgA codominant staining was disallowed. A distinctive immunohistologic feature of IgAN in comparison with other immune complex-mediated glomerulopathies, in addition to the predominance of IgA immunostaining, was a high frequency (67%) of patients with greater lambda- than kappa-immunoglobulin light chain immunostaining. There was no correlation between the absolute or relative intensities or frequencies of IgA, IgG, or IgM immunostaining and the severity of glomerular disease; however, the presence of capillary wall immune deposits correlated with more severe disease. Terminal complement components were consistently present and were more conspicuous in more severely injured glomeruli. Immunostaining for the early classical complement activation pathway component C1q was absent or scanty in IgAN. This finding was particularly useful in the immunohistologic differentiation of IgAN from proliferative lupus glomerulonephritis, which was the form of glomerulonephritis with the greatest overlap with IgAN with respect to IgA immunostaining. When the diagnostic criteria for IgAN were 2+ or greater, dominant or codominant mesangial IgA immunostaining and less than 2+ C1q immunostaining, an immunohistologic diagnosis of IgAN was made with 98% accuracy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142256     DOI: 10.1016/s0272-6386(88)80022-2

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  47 in total

Review 1.  Progress in molecular and genetic studies of IgA nephropathy.

Authors:  J Novak; B A Julian; M Tomana; J Mesteck
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

2.  Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.

Authors:  Hitoshi Suzuki; Run Fan; Zhixin Zhang; Rhubell Brown; Stacy Hall; Bruce A Julian; W Winn Chatham; Yusuke Suzuki; Robert J Wyatt; Zina Moldoveanu; Jeannette Y Lee; James Robinson; Milan Tomana; Yasuhiko Tomino; Jiri Mestecky; Jan Novak
Journal:  J Clin Invest       Date:  2009-05-26       Impact factor: 14.808

Review 3.  Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies.

Authors:  Krzysztof Kiryluk; Jan Novak; Ali G Gharavi
Journal:  Annu Rev Med       Date:  2012-10-16       Impact factor: 13.739

Review 4.  Pathology of IgA nephropathy.

Authors:  Ian S D Roberts
Journal:  Nat Rev Nephrol       Date:  2014-05-27       Impact factor: 28.314

Review 5.  Glycosylation of IgA1 and pathogenesis of IgA nephropathy.

Authors:  Jan Novak; Bruce A Julian; Jiri Mestecky; Matthew B Renfrow
Journal:  Semin Immunopathol       Date:  2012-03-21       Impact factor: 9.623

6.  Clinicopathological significance of light chain deposition in IgA nephropathy.

Authors:  Ritsuko Katafuchi; Hiroshi Nagae; Kosuke Masutani; Toshiaki Nakano; Mikio Munakata; Kazuhiko Tsuruya; Koji Mitsuiki
Journal:  Clin Exp Nephrol       Date:  2021-03-01       Impact factor: 2.801

7.  In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells.

Authors:  Takeshi Yanagihara; Rhubell Brown; Stacy Hall; Zina Moldoveanu; Alice Goepfert; Milan Tomana; Bruce A Julian; Jiri Mestecky; Jan Novak
Journal:  Results Immunol       Date:  2012-01-01

Review 8.  Treatment of IgA nephropathy.

Authors:  C Y Lin
Journal:  Springer Semin Immunopathol       Date:  1994

9.  Clinicopathological significance of monoclonal IgA deposition in patients with IgA nephropathy.

Authors:  Hiroshi Nagae; Akihiro Tsuchimoto; Kazuhiko Tsuruya; Shota Kawahara; Yukiko Shimomura; Hideko Noguchi; Kosuke Masutani; Ritsuko Katafuchi; Takanari Kitazono
Journal:  Clin Exp Nephrol       Date:  2016-05-12       Impact factor: 2.801

10.  IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1.

Authors:  Hitoshi Suzuki; Zina Moldoveanu; Stacy Hall; Rhubell Brown; Huong L Vu; Lea Novak; Bruce A Julian; Milan Tomana; Robert J Wyatt; Jeffrey C Edberg; Graciela S Alarcón; Robert P Kimberly; Yasuhiko Tomino; Jiri Mestecky; Jan Novak
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.